The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase 2b Study of Adults with Active Psoriatic Arthritis -

The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase 2b Study of Adults with Active Psoriatic Arthritis
Information type: Randomised controlled trials
Source: Arthritis & Rheumatology
Specialities: Musculo-skeletal disorders | Skin disorders
Summary
RCT (n=165) found at week 16, there was a higher response rate (ACR20) with clazakizumab (CL) 100 mg vs. placebo (52.4% vs 29.3%; p=0.039). ACR20 responses with CL 25 mg and CL 200 mg were not significantly different vs. placebo.
UKMi comment
Clazakizumab is a monoclonal antibody with high affinity and specificity for the interleukin (IL)-6 cytokine. This is the first clinical trial of an IL-6-targeted therapy in psoriatic arthritis. Further studies are required to confirm the appropriate dose due to the lack of dose response in this study.
Related links: